Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon:
Coronary artery disease affects more than 3 million Americans every year, and it has a number of risk factors. Historically, coronary CTA has been used to assess and provide details about a patient’s atherosclerosis. New evidence is out this week, revealing that not all risk factors are equal, nor do they act on body in the same way. Look for details later this week about the impact of these factors.
For more coronary CTA coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Since the start of the COVID-19 pandemic, most attention has been paid to the pulmonary, cardiovascular, neurological, and gastrointestinal impacts of the virus. But, investigators are now learning that the effects of infection go further – it can affect vision. This week, look for coverage of how COVID-19 can impact the eyes and how it presents on imaging.
For more coverage of imaging and the eye, click here.
Thrombectomy, stents, or anti-thrombotic medication are typically used to treat patients who are suffering from acute ischemic stroke. But, providers can often face questions about making the right decision. In Radiology, investigators from the University of California at San Francisco published their study results, showing that integrating intra-procedural 3T MRI into acute ischemic stroke treatment can effectively guide decision-making. Look for details later this week.
For additional coverage of imaging for stroke, click here.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.